🇺🇸 FDA
Patent

US 12018015

Methods and compositions for targeting PD-L1

granted A61KA61K31/506A61K31/5377

Quick answer

US patent 12018015 (Methods and compositions for targeting PD-L1) held by Aligos Therapeutics, Inc. expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aligos Therapeutics, Inc.
Grant date
Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/506, A61K31/5377, A61K31/658, A61K45/06